Prolacta Bioscience, founded in 1999, is a pioneer in the biotechnology and life sciences sector, headquartered in the United States. The company’s mission is encapsulated in its slogan: "Advancing the Science of Human Milk.” Prolacta is transforming neonatal care by utilizing human milk-based nutritional products designed specifically for the most vulnerable preemies in hospital neonatal units across the nation.
The company operates within the health care and nutrition industries, dedicating its research and product development to enhancing outcomes for critically ill infants. The last recorded investment in the company was an $8.91M venture round in May 2018. Strategic investors should note Prolacta's commitment to reshaping nutritional standards in neonatal care, positioning it as a leading figure in its niche market.